Search Results
Your search for M. Steven Piver, MD matches 7 pages
Showing 1 - 7Kunle Odunsi, MD, PhD, FRCOG, FACOG, Elected At-Large Director of SITC Board of Directors
Elected by a body of fellow immunotherapy researchers from across the globe, Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, has been named At-Large Director of the Society for Immunotherapy of Cancer (SITC) Board of Directors. Dr. Odunsi will begin his ...
Kunle Odunsi, MD, PhD, FRCOG, FACOG, Elected to Lead AACR Immunology Working Group
Chosen for his passion and leadership in immunotherapy research, Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, was elected as the Cancer Immunology Working Group (CIMM) Chairperson-Elect for 2020–2021. CIMM is a scientific working group within the...
Screening for Ovarian Cancer: A Gynecologic Oncologist’s Perspective
The recent U.S. Preventive Services Task Force (USPSTF) Reaffirmation Recommendation Statement concluded that in the population of asymptomatic women without known genetic mutations that increase risk for ovarian cancer, clinicians should not screen for ovarian cancer using transvaginal ultrasound...
Disclosure: Appropriate or Not?
The ASCO Post is an outstanding publication that I always look forward to reading. I also understand there are policies and rules to be followed, particularly regarding conflicts of interest and disclosures from contributors. I am writing in regard to “Cancer Has Made Me A Better Doctor,” by David...
Roswell Park Cancer Institute Appoints New Leadership Team
Roswell Park Cancer Institute recently announced a restructuring of its leadership. “In many cases, these new appointments represent Roswell Park Cancer Institute parlaying our own existing strengths and talents,” says President and CEO Candace Johnson, PhD. “Restructuring some of these positions...
Researchers Identify Priority Targets for Immunotherapy in Epithelial Ovarian Cancer
Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. Based on their findings, the researchers have...
Recurrent Ovarian Cancers Respond to Cancer Vaccine After ‘Reprogramming’ With Decitabine
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a...
